Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.

6074Background: Selpercatinib is a first-in-class, CNS active, highly selective, and potent RET kinase inhibitor which has demonstrated durable antitumor activity in patients (pts) with RET altered...